The Lancet Rheumatology : Impact Factor & More
eISSN: 2665-9913pISSN: 2665-9913
Share this on:
Key Metrics
CiteScore 
23
Eigenfactor
< 0.001
Impact Factor
5 - 10
Scite Index
0.89 5-Year SI
SJR
Q1Immunology
SNIP
5.68
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on The Lancet Rheumatology
The Lancet Rheumatology Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
SJR
| Overview | |
| Publisher | ELSEVIER |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2019 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in The Lancet Rheumatology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in The Lancet Rheumatology
Long-term treatment transition patterns after intensive treatment strategies in early psoriatic arthritis: insights from the GOLMePsA clinical trial.
- 8 May 2026
- The Lancet. Rheumatology
When one joint matters: the monoarticular blind spot in inflammatory arthritis.
- 8 May 2026
- The Lancet. Rheumatology
Enpatoran: promising mechanism, pharmacodynamic challenge.
- 7 May 2026
- The Lancet. Rheumatology
Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial.
- 7 May 2026
- The Lancet. Rheumatology
Prevalence and determinants of sacroiliac joint bone marrow oedema in the general population in Germany: a population-based cross-sectional study.
- 6 May 2026
- The Lancet. Rheumatology
COSPIRIT-JIA: considering biologic choices in juvenile spondyloarthritis.
- 1 May 2026
- The Lancet. Rheumatology
Long-term treatment transition patterns after intensive treatment strategies in early psoriatic arthritis: insights from the GOLMePsA clinical trial.
- 8 May 2026
- The Lancet. Rheumatology
When one joint matters: the monoarticular blind spot in inflammatory arthritis.
- 8 May 2026
- The Lancet. Rheumatology
Enpatoran: promising mechanism, pharmacodynamic challenge.
- 7 May 2026
- The Lancet. Rheumatology
Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial.
- 7 May 2026
- The Lancet. Rheumatology
Prevalence and determinants of sacroiliac joint bone marrow oedema in the general population in Germany: a population-based cross-sectional study.
- 6 May 2026
- The Lancet. Rheumatology
COSPIRIT-JIA: considering biologic choices in juvenile spondyloarthritis.
- 1 May 2026
- The Lancet. Rheumatology
FAQs on The Lancet Rheumatology
How long has The Lancet Rheumatology been actively publishing? 
What is the publishing frequency of The Lancet Rheumatology?
How many articles did The Lancet Rheumatology publish last year?
What is the eISSN & pISSN for The Lancet Rheumatology?
What is Citescore for The Lancet Rheumatology?
What is SNIP score for The Lancet Rheumatology?
What is the SJR for The Lancet Rheumatology?
Who is the publisher of The Lancet Rheumatology?
